Evidence map›Paper›PMID 30825109›Full record

ArticleDigestive diseases and sciences2019

Association Between Cannabis Use and Complications Related to Crohn's Disease: A Retrospective Cohort Study.

Chimezie Mbachi, Bashar Attar, Yuchen Wang, Isaac Paintsil, Benjamin Mba, Setri Fugar, Rohit Agrawal, Roberto Carlos Simons-Linares, Palash Jaiswal, William Trick and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Under the Influence: Cognitive Effects of Medical Marijuana on Developing Minds.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  4. The Impact of the CBMolecules (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Cannabidiol Isolated FromFrontiers in pharmacology · 2021
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Chimezie MbachiJohn H Stroger Hospital of Cook County, Chicago, IL, USA. chimeziembachi@gmail.com.ORCID 0000-0002-4046-282X
Bashar AttarJohn H Stroger Hospital of Cook County, Chicago, IL, USA.
Yuchen WangJohn H Stroger Hospital of Cook County, Chicago, IL, USA.
Isaac PaintsilJohn H Stroger Hospital of Cook County, Chicago, IL, USA.
Benjamin MbaJohn H Stroger Hospital of Cook County, Chicago, IL, USA.
Setri FugarRush University Medical Centre, Chicago, IL, USA.
Rohit AgrawalJohn H Stroger Hospital of Cook County, Chicago, IL, USA.
Roberto Carlos Simons-LinaresGastroenterology and Hepatology Department, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USA.
Palash JaiswalSUNY Downstate Medical Centre, New York, NY, USA.
William TrickJohn H Stroger Hospital of Cook County, Chicago, IL, USA.
Vikram KotwalJohn H Stroger Hospital of Cook County, Chicago, IL, USA.
John H. Stroger, Jr. Hospital of Cook County · USCleveland Clinic · USRush University Medical Center · USSUNY Downstate Health Sciences University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCrohn's disease is an idiopathic inflammatory process that is occasionally associated with complications, which cause significant morbidity and mortality. The anti-inflammatory effect of cannabis in intestinal inflammation has been shown in several experimental models; it is unknown whether this correlates with fewer complications in Crohn's disease patients.

aimsTo compare the prevalence of Crohn's disease-related complications among cannabis users and non-users in patients admitted with a primary diagnosis of Crohn's disease or a primary diagnosis of Crohn's related complication and a secondary diagnosis of Crohn's disease between 2012 and 2014.

methodsWe used data from the Healthcare Cost and Utilization Project-National Inpatient Sample. Cannabis users (615) were compared directly after propensity score match to non-users, in aspects of various complications and clinical end-points.

resultsAmong matched cohorts, Cannabis users were less likely to have the following: active fistulizing disease and intra-abdominal abscess (11.5% vs. 15.9%; aOR 0.68 [0.49 to 0.94], p = 0.025), blood product transfusion (5.0% vs. 8.0%; aOR 0.48 [0.30 to 0.79], p = 0.037), colectomy (3.7% vs. 7.5%; aOR 0.48 [0.29-0.80], p = 0.004), and parenteral nutrition requirement (3.4% vs. 6.7%, aOR 0.39 [0.23 to 0.68], p = 0.009).

conclusionCannabis use may mitigate several of the well-described complications of Crohn's disease among hospital inpatients. These effects could possibly be through the effect of cannabis in the endocannabinoid system.

Indexed as

Abdominal AbscessIntestinal FistulaAdultBlood TransfusionColectomyCorrelation of DataCrohn DiseaseFemaleHumansMaleMarijuana AbuseMiddle AgedParenteral NutritionPrevalencePropensity ScoreRetrospective StudiesCannabisComplicationsCrohn’sParenteral nutrition

Identifiers

PMID30825109
OpenAlexW2920326336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.